PanTher Reimagines Cardiology Interventions As Precision Oncology Platform

 
• By Ayisha Sharma

Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.    

Emerging Company Profile: PanTher Therapeutics
Drug-Eluting Stents First Revolutionized The Cardiology Space • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs